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Improved cardiac performance with human calcitonin 
gene related peptide in patients with congestive heart 
failure 
C Gennari, R Narni, D Agnusdei, J A Fischer 
Abstract 
Study objective - The aim of the study was to 
assess the cardiovascular effects of human calcito- 
nin gene related peptide (CGRP) in patients with 
congestive heart failure. 
Design - The effects of CGRP I1 (or p), 12.5 
pgh-', given by intravenous infusion for 24 h to 
digitalised patients with congestive heart failure, 
were assessed by measurement of cardiac functional 
indices. 
Patients - Five patients (four female) were stu- 
died. Age was 73-82 years. Three were in New York 
Heart Association phase I11 and two in phase IV. 
Measurements and main results - The pre-ejection 
period to left ventricular ejection time ratio and the 
Q T  distance adjusted for heart rate were lowered by 
21% and 4% respectively. The left ventricular 
shortening index was raised by 43%. The arterial 
pressure and heart rate did not change consistently. 
Conclusion - Calcitonin gene related peptide 
improves myocardial contractility in patients with 
congestive heart failure. This is the first time this has 
been shown. 
Congestive heart failure is usually caused by reduced 
cardiac output as a result of impaired myocardial 
contractility. Its treatment includes positive inotropic 
agents, eF, digitalis, as well as vasodilator and diuretic 
therapy. Calcitonin gene related peptide (CGRP) is a 
recently discovered neuropeptide with potent 
cardiovascular effects that include positive 
chronotropic and inotropic actions on the heart, 
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vasodilatation, and hyp~tension.*-~ The stimulation of 
the heart rate and coronary vasodilatation presumably 
depend on the local release of CGRP from afferent 
nerve fibres in the heart induced by capsaicin and 
interaction with receptors linked to cyclic adenosine 
monophosphate The improved 
ventricular contractility of CGRP was suppressed in 
normal human subjects through blockade of 
adrenergic receptors, and may be driven by reflex 
sympathetic ~timulation.~ Here we show evidence of 
improved ventricular contractility with CGRP as 
recorded with non-invasive techiques in five digitalised 
patients with congestive heart failure. 
Methods 
We studied four female and one male patient aged 73 to 
82 years with congestive heart failure, three in New 
York Heart Association phase I11 and two in phase 
IV. Four patients had coronary artery disease and the 
fifth had hypertrophic cardiomyopathy. Body weight 
was 44-66 kg, and height 147-158 cm. Informed 
consent about the experimental treatment with CGRP 
was obtained from all patients, and the study was 
approved by the appropriate ethics committee. 
The patients were treated with oral P-methyldigoxin 
(Lanitop, Boehringer, Mannheim, W Germany), 0.6 
mg (0.77 nmol) per day for three days, followed by 0.3 
mg (0.39 nmol) per day for four days (figure), after 
which they were given human CGRP I1 (or P) 
(Peninsula Laboratories, Belmont, CAY USA), 12.5 
pgeh-' (3.3 nmol) by intravenous minipump infusion 
for 24 h. 
The systemic arterial pressure was monitored 
continuously by intra-arterial manometry. The 
duration of the pre-ejection period and the left 
ventricular ejection time were determined using 
electrocardiography, phonocardiography, and 
external carotid pulse tracings. l8 The corrected QT 
interval (QTJ was calculated by dividing QT by the 
square root of the preceding R-R interval. The left 
ventricular cavity was measured before and during the 
infusions with CGRP by M mode echocardiography at 
the end diastolic and the end systolic filling times." 
The left ventricular shortening index was calculated as 
the ratio between the left ventricular end diastolic 
minus the end systolic diameters, and the left 
ventricular end diastolic diameter. 
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Serum concentrations of digoxin were measured by 
radioimmunoassay.20 Total serum calcium was 
measured by atomic absorption spectrophotometry 
(Perkin-Elmer, Norwalk, CN, USA).” 
Statistical analysis was by paired t test.22 Values are 
given as means (SEM). 
Results 
Congestive heart failure was treated with 
P-methyldigoxin and therapeutic serum concen- 
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trations (0.7-1.8 nmol.litre-’) were achieved (figure).” 
The heart rate was lowered (p<O.OS), but the 
pre-ejection period to left ventricular ejection time 
ratio and the QT, intervals were only minimally 
decreased, from 0.50 (SEM 0.02) to 0.47(0.02) 
(p<O.OI), and from 0.43(0.03) s to 0.42(0.03) s, 
respectively (p<O.Ol). Myocardial contractility 
remained largely unchanged during the seven day 
treatment with therapeutic doses of P-methyldigoxin. 
As a result, the patients were essentially refractory to 
treatment with digoxin. No other treatment was used. 
Human CGRP I1 was then given as an intravenous 
infusion for 24 h at a rate previously used in normal 
s~bjects.’~ The arterial pressure was minimally 
lowered and the heart rate remained slightly raised 
(p>O.OS), but the pre-ejection period to left 
ventricular ejection time ratio was lowered from 
0.47(0.03) to 0.37(0.03) (normal <0.35; p<O.OOl), 
and the QT, intervals were shortened from 0.42(0.03) 
to 0.41(0.03) s (pcO.01). The left ventricular 
shortening index was raised from 0.28(0.02) to 
0.42(0.04) (normal >0.29; p<O.Ol). Improved 
contractility of the heart ventricle was evident with 
CGRP in all the five patients. With the dose of CGRP 
used, the undesired hypotensive and positive 
chronotropic effects were limited and did not affect the 
therapeutic efficacy of CGRP on ventricular 
contractility. All five patients noted subjective 
improvements. With CGRP, serum calcium levels 
remained unchanged: before CGRP 2.29(0.03) 
mmol*litre-’; after CGRP 2.29(0.04) mmol*litre-’. 
Discussion 
The improvement of myocardial contractility is a 
principal object of the treatment of congestive heart 
failure. Digitalis has limited efficacy and potential 
toxicity. P Adrenergic agonists are thought to exert 
positive inotropic effects on the heart through 
stimulation of cyclic AMP production.’ As a result, 
calcium influx is stimulated in myocardial cells.24 The 
improved ventricular contractility of CGRP was 
suppressed in normal subjects through blockade of 
adrenergic receptors, and may result in part from 
reflex sympathetic st im~lation.~ Coronary 
vasodilatation is achieved through interaction of CGRP 
with its rece tors and stimulation of cyclic AMP 
Here we have used non-invasive procedures. 
Reduction of systolic time intervals is brought about 
through positive inotropic agents and reduction in 
afterload, eg, due to vasodilatation. ’* The combined 
positive inotropic action on the heart and vasodilator 
properties of CGRP explain the improvement of 
congestive heart failure in the present patients. In view 
of the vasodilator activity of CGRP it remains to be 
shown whether cardiac function is also ameliorated 
through the positive inotropic action of the peptideZ5 in 
patients with congestive heart failure. 
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